AcuCort

In addition to the prior subscription commitments, Jonas Jönmark has entered into a new commitment to subscribe for further units totalling approximately SEK 1 million. These commitments are made on the same terms as those offered to other investors. This demonstrates the management’s continued confidence in AcuCort’s prospects.

Altogether, subscription commitments from the Board of Directors, management, and major shareholders now amount to approximately SEK 14.6 million, representing around 33 per cent of the rights issue and aligning with their pro rata shares. The subscription period for the rights issue runs from 9 January 2025 to 24 January 2025.

For further information: 
Jonas Jönmark, vd, AcuCort AB
Phone: 070 365 5400
E-mail: jonas.jonmark@acucort.se

About AcuCort AB (publ)
AcuCort has developed and is commercializing Zeqmelit®, a new rapidly dissolving oral film placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy, and for the treatment of patients with COVID-19 requiring supplemental oxygen therapy. Zeqmelit® is approved in Sweden, Denmark, Norway, and Finland. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market. Visit www.acucort.se for more information.